-transparent.png){kind=logo}
A selective, high-affinity A(2B) adenosine receptor (AR) antagonist will be useful as a pharmacological tool to help determine the role of the A(2B)AR in inflammatory diseases and angiogenic diseases. Based on early A(2B)AR-selective ligands with nonoptimal pharmaceutical properties, such as 15 (MRS 1754: K(i)(hA(2B)) = 2 nM; K(i)(hA(1)) = 403 nM; K(i)(hA(2A)) = 503 NM, and K(i)(hA(3)) = 570 nM), several groups have discovered second-generation A(2B)AR ligands that are suitable for development. Scientists at CV Therapeutics have discovered the selective, high-affinity A(2B)AR antagonist 22, a 8-(4-pyrazolyl)-xanthine derivative, (CVT-6883, K(i)(hA(2B)) = 22 nM; K(i)(hA(1)) = 1,940 nM; K(i)(hA(2A)) = 3,280; and K(i)(hA(3)) = 1,070 nM). Compound 22 has demonstrated favorable pharmacokinetic (PK) properties (T(1/2) = 4 h and F > 35% rat), and it is a functional antagonist at the A(2B)AR(K (B) = 6 nM). In a mouse model of asthma, compound 22 demonstrated a dose-dependent efficacy supporting the role of the A(2B)AR in asthma. In two Phase I clinical trails, 22 (CVT-6883) was found to be safe, well tolerated, and suitable for once-daily dosing. Baraldi et al. have independently discovered a selective, high-affinity A(2B)AR antagonist, 30 (MRE2029F20), 8-(5-pyrazolyl)-xanthine (K(i)(hA(2B)) = 5.5 nM; K(i)(hA(1)) = 200 nM; K(i)(hA(2A), A(3)) > 1,000, that has been selected for development in conjunction with King Pharmaceuticals. Compound 30 has been demonstrated to be a functional antagonist of the A(2B)AR, and it has been radiolabeled for use in pharmacological studies. A third compound, 58 (LAS-38096), is a 2-aminopyrimidine derivative (discovered by the Almirall group) that has high A(2B)AR affinity and selectivity (K(i)(hA(2B)) = 17 nM; K(i)(hA(1)) > 1,000 nM; K(i)(hA(2A)) > 2,500; and K(i)(hA(3)) > 1,000 nM), and 58 has been moved into preclinical safety testing. A fourth selective, high-affinity A(2B)AR antagonist, 54 (OSIP339391 K(i))(hA(2B)) = 0.5 nM; K(i))(hA(1)) = 37 nM; K(i))(hA(2A)) = 328; and K(i))(hA(3)) = 450 nm) was discovered by the OSI group. The three highly selective, high-affinity A(2B)AR antagonists that have been selected for development should prove useful in subsequent clinical trials that will establish the role of the A(2B)ARs in various disease states.
Rao V Kalla, and
Jeff Zablocki, and
Mojgan Aghazadeh Tabrizi, and
Pier Giovanni Baraldi
December 2005,
Mini reviews in medicinal chemistry,
Rao V Kalla, and
Jeff Zablocki, and
Mojgan Aghazadeh Tabrizi, and
Pier Giovanni Baraldi
January 2009,
Handbook of experimental pharmacology,
Rao V Kalla, and
Jeff Zablocki, and
Mojgan Aghazadeh Tabrizi, and
Pier Giovanni Baraldi
December 2000,
Current medicinal chemistry,
Rao V Kalla, and
Jeff Zablocki, and
Mojgan Aghazadeh Tabrizi, and
Pier Giovanni Baraldi
January 2006,
Current medicinal chemistry,
Rao V Kalla, and
Jeff Zablocki, and
Mojgan Aghazadeh Tabrizi, and
Pier Giovanni Baraldi
September 2006,
Medicinal research reviews,
Rao V Kalla, and
Jeff Zablocki, and
Mojgan Aghazadeh Tabrizi, and
Pier Giovanni Baraldi
May 2011,
Biochimica et biophysica acta,
Rao V Kalla, and
Jeff Zablocki, and
Mojgan Aghazadeh Tabrizi, and
Pier Giovanni Baraldi
September 2007,
ChemMedChem,
Rao V Kalla, and
Jeff Zablocki, and
Mojgan Aghazadeh Tabrizi, and
Pier Giovanni Baraldi
January 2019,
Current pharmaceutical design,
Rao V Kalla, and
Jeff Zablocki, and
Mojgan Aghazadeh Tabrizi, and
Pier Giovanni Baraldi
January 2001,
Farmaco (Societa chimica italiana : 1989),
Rao V Kalla, and
Jeff Zablocki, and
Mojgan Aghazadeh Tabrizi, and
Pier Giovanni Baraldi
October 2019,
International journal of molecular sciences,
